Powering the Nation's Emergency-Ready Cold Chain and Logistics Network
Callan JMB Inc. (Nasdaq: CJMB) is an integrative logistics company that supports the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, with core competencies in pharmaceuticals, medical supplies, and emergency asset materials tied to the U.S. Strategic National Stockpile.
Identifying The Opportunity
KEY LEVELS
Key Level 1: $2.65 (+7.32%)
Key Level 2: $3.22 (+30.68%)
Key Level 3: $3.94 (+59.62%)
Support: $1.83
Callan JMB Inc.
Vertically Integrated Cold Chain Platform
- Callan JMB is building a vertically integrated pharmaceutical logistics platform, controlling the process from specialty packaging design through fulfillment and real-time shipment monitoring at its licensed, temperature-controlled facilities in Spring Branch, Texas.
- The platform includes in-house design and manufacturing of reusable VIP thermal shippers, a proprietary SHIP2Q sanitizing and recertification process, and the company's own Sentry monitoring technology, giving Callan JMB control over packaging, compliance, and visibility that many competitors outsource to third parties.
- Partnerships with Attune Biotech and Alabama State University extend that same platform into manufacturing oversight and commercialization, applying Callan JMB's cold chain and emergency preparedness infrastructure to pharmaceutical production and onshoring for federal, healthcare, and government customers.
Operational Momentum and Scaling
- Callan JMB is scaling through a multi-variant growth strategy, expanding beyond its core cold chain and emergency preparedness business into new subsidiaries such as Atlas Complex, Callan Power, and Callan JMB Services India.
- Government and healthcare partnerships, including an eight-year, $9.1 million emergency preparedness contract with the City of Chicago and multi-year agreements with the Oregon Health Authority and Texas Department of State Health Services, provide a recurring revenue base.
- New initiatives, including the Attune Biotech manufacturing oversight and commercialization agreement, estimated at $50 to $75 million in total revenue, and the pending Reger Oil asset acquisition through Callan Power, extend the company's path toward diversified, long-term growth.
Positioning for Long-Term Growth
- Callan JMB has managed more than three million pharmaceutical shipments since 2007, with a 99.9 percent success rate, backed by founder and CEO Wayne Williams' background as Associate Director of Logistics for the Strategic National Stockpile.
- Callan JMB is positioning for long-term growth by diversifying beyond cold chain logistics, building the 150+ acre Atlas Complex pharmaceutical onshoring campus in Brewton, Alabama, in partnership with Alabama State University.
- A new agreement announced in January 2026 with Attune Biotech, valued at an estimated $50 to $75 million in total revenue, supports the company's manufacturing oversight and commercialization pipeline.
Key Financial Highlights:
- Revenue: $2,482,468, down from $3,115,687 (about 20% lower)
- Gross profit: $1,185,180, essentially flat versus $1,256,963
- SG&A expenses: $4,233,015, up from $3,901,878
- Loss from operations: $(3,047,835), wider than $(2,644,915) a year earlier
- Net loss: $(4,446,977), nearly 70% higher than $(2,641,986) in the prior-year period
- Net loss per share: $(0.80), versus $(0.63)
Introducing the Leadership Team of Callan JMB Inc. (Nasdaq: CJMB)
Wayne Williams
Chief Executive Officer
Wayne Williams is the Founder, Chairman, President and Chief Executive Officer of Callan JMB Inc. He previously served as Associate Director of Logistics for the Strategic National Stockpile from its inception through its post-9/11 expansion. Under his leadership, Callan JMB has grown its cold chain logistics and emergency preparedness business, managing more than three million pharmaceutical shipments since 2007 with a 99.9 percent success rate, while expanding the company through new subsidiaries including Atlas Complex, Callan Power, and Callan JMB Services India. He oversees the company's government and healthcare partnerships, including its work with the City of Chicago, the Oregon Health Authority, and the Texas Department of State Health Services, as well as its capital markets strategy as a Nasdaq-listed public company.
Scott Bullard
Chief Operating Officer
Scott Bullard serves as Chief Operating Officer of Callan JMB Inc. He oversees the company's day-to-day logistics, warehousing, and emergency preparedness operations across its licensed, temperature-controlled facilities, working closely with government and healthcare clients including the City of Chicago, the Oregon Health Authority, and the Texas Department of State Health Services.
Since Callan JMB's February 2025 IPO, the company has continued to expand its service offerings and government contracts while pursuing new subsidiaries such as Atlas Complex and Callan Power, supporting the company's broader positioning as a diversified logistics and emergency preparedness provider.
David J. Croyle, M.D.
Chief Medical Officer
David J. Croyle, M.D. serves as Chief Medical Officer of Callan JMB Inc. He provides clinical and medical oversight for the company's healthcare logistics operations, supporting the safe handling, storage, and distribution of pharmaceuticals, medical supplies, and emergency asset materials, including materials tied to the U.S. Strategic National Stockpile. He works closely with the company's government and healthcare partners to help ensure compliance across the company's licensed, temperature-controlled facilities.
We get our information from SEC filings and verified public sources.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
https://www.callanjmb.com/ https://www.sec.gov/ (CJMB SEC Filings) https://www.stocktitan.net/ (SEC filings tracker and news feed) https://finance.yahoo.com/ https://www.google.com/finance/ https://stockanalysis.com/ https://www.tradingview.com/symbols/NASDAQ-CJMB/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Pursuant to an agreement between JRZ Capital and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $CJMB via digital communications beginning August 24th, 2026 ending September 4th, 2026. Virtus will be paid $75,000 from JRZ Capital.
